{"id":2265,"date":"2014-09-30T20:15:39","date_gmt":"2014-09-30T20:15:39","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=2265"},"modified":"2014-09-30T20:19:35","modified_gmt":"2014-09-30T20:19:35","slug":"hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/","title":{"rendered":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich &#8211; eine Phase-III-Studie"},"content":{"rendered":"<p>AMB 2014, 48, 61a &nbsp; Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich &#8211; eine Phase-III-Studie Fazit: F\u00fcr unbehandelte Patienten mit chronischer Hepatitis\u00a0C ist die einmal t\u00e4gliche Einnahme einer Kombinationstablette, bestehend aus Ledipasvir und Sofosbuvir f\u00fcr 12\u00a0Wochen eine einfache, wirksame und offensichtlich gut vertr\u00e4gliche Therapie mit einer sehr hohen Wahrscheinlichkeit, das Virus anhaltend zu [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2014, 48, 61a &nbsp; Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich &#8211; eine Phase-III-Studie Fazit: F\u00fcr unbehandelte Patienten mit chronischer Hepatitis\u00a0C ist die einmal t\u00e4gliche Einnahme einer Kombinationstablette, bestehend aus Ledipasvir und Sofosbuvir f\u00fcr 12\u00a0Wochen eine einfache, wirksame und offensichtlich gut vertr\u00e4gliche Therapie mit einer sehr hohen Wahrscheinlichkeit, das Virus anhaltend zu [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[1394,318,1384,1367,1368,1393,1369,321,1395,1396],"class_list":["post-2265","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-einer","tag-hepatitis-c","tag-in","tag-ion-1-studie","tag-ledipasvir","tag-plus","tag-sofobuvir","tag-sofosbuvir","tag-tablette","tag-taeglich-eine-phase-iii-studie"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - Der Arzneimittelbrief<\/title>\n<meta name=\"description\" content=\"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-30T20:15:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-09-30T20:19:35+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"henk-amb\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"henk-amb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/\"},\"author\":{\"name\":\"henk-amb\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"headline\":\"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich &#8211; eine Phase-III-Studie\",\"datePublished\":\"2014-09-30T20:15:39+00:00\",\"dateModified\":\"2014-09-30T20:19:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/\"},\"wordCount\":461,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"einer\",\"Hepatitis C\",\"in\",\"ION-1-Studie\",\"Ledipasvir\",\"plus\",\"Sofobuvir\",\"Sofosbuvir\",\"Tablette\",\"t\u00e4glich - eine Phase-III-Studie\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/\",\"name\":\"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2014-09-30T20:15:39+00:00\",\"dateModified\":\"2014-09-30T20:19:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\"},\"description\":\"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich &#8211; eine Phase-III-Studie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/2e7981c97826a4941311e607c145d937\",\"name\":\"henk-amb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g\",\"caption\":\"henk-amb\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - Der Arzneimittelbrief","description":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/","og_locale":"de_DE","og_type":"article","og_title":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - Der Arzneimittelbrief","og_description":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2014-09-30T20:15:39+00:00","article_modified_time":"2014-09-30T20:19:35+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"henk-amb","twitter_misc":{"Verfasst von":"henk-amb","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/"},"author":{"name":"henk-amb","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"headline":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich &#8211; eine Phase-III-Studie","datePublished":"2014-09-30T20:15:39+00:00","dateModified":"2014-09-30T20:19:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/"},"wordCount":461,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["einer","Hepatitis C","in","ION-1-Studie","Ledipasvir","plus","Sofobuvir","Sofosbuvir","Tablette","t\u00e4glich - eine Phase-III-Studie"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/","name":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2014-09-30T20:15:39+00:00","dateModified":"2014-09-30T20:19:35+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937"},"description":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich - eine Phase-III-Studie - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/hepatitis-c-ledipasvir-plus-sofosbuvir-in-einer-tablette-taeglich-eine-phase-iii-studie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Hepatitis C: Ledipasvir plus Sofosbuvir in einer Tablette t\u00e4glich &#8211; eine Phase-III-Studie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/2e7981c97826a4941311e607c145d937","name":"henk-amb","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/314c85e3c5c37749a415d1df0e5fe7642768dd0d2f48f8a4fea70eae9b7499fc?s=96&d=mm&r=g","caption":"henk-amb"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=2265"}],"version-history":[{"count":9,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2265\/revisions"}],"predecessor-version":[{"id":2323,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/2265\/revisions\/2323"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=2265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=2265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=2265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}